Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 bapineuzumab in APOE ε4 carriers with mild to moderate Alzheimer's disease
2007-005995-14Phase 3Completed
- Sponsor
- Pfizer
- Start
- Feb 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Bapineuzumab 0.5 mg/kg with Placebo (2 arms). Primary endpoints: ADAS-Cog/11 total score and DAD. Started Feb 2008; status: completed.
02
Drugs
bapineuzumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2007-005995-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005995-14.